Logo
Unionpedia
Communication
Get it on Google Play
New! Download Unionpedia on your Androidâ„¢ device!
Install
Faster access than browser!
 

Linzagolix

Index Linzagolix

Linzagolix (developmental code names KLH-2109, OBE-2109) is a small-molecule, non-peptide, orally active gonadotropin-releasing hormone antagonist (GnRH antagonist) which is under development by Kissei Pharmaceutical and ObsEva for the treatment of uterine leiomyoma and endometriosis. [1]

3 relations: Gonadotropin-releasing hormone antagonist, Gonadotropin-releasing hormone receptor, List of investigational hormonal agents.

Gonadotropin-releasing hormone antagonist

Gonadotropin-releasing hormone antagonists (GnRH antagonists) are a class of medications that antagonize the gonadotropin-releasing hormone receptor (GnRH receptor) and thus the action of gonadotropin-releasing hormone (GnRH).

New!!: Linzagolix and Gonadotropin-releasing hormone antagonist · See more »

Gonadotropin-releasing hormone receptor

The gonadotropin-releasing hormone receptor (GnRHR), also known as the luteinizing hormone releasing hormone receptor (LHRHR), is a member of the seven-transmembrane, G-protein coupled receptor (GPCR) family.

New!!: Linzagolix and Gonadotropin-releasing hormone receptor · See more »

List of investigational hormonal agents

This is a list of investigational hormonal agents, or hormonal agents that are currently under development for clinical use but are not yet approved.

New!!: Linzagolix and List of investigational hormonal agents · See more »

Redirects here:

KLH 2109, KLH-2109, KLH2109, OBE 2109, OBE-2109, OBE2109.

References

[1] https://en.wikipedia.org/wiki/Linzagolix

OutgoingIncoming
Hey! We are on Facebook now! »